AIM: To combine and test the EORTC questionnaires for assessing quality of life (HRQL) for oesophageal (QLQ-OES18) and stomach cancer (QLQ-STO22), into a single questionnaire for tumours of the oesophagus, oesophago-gastric junction or stomach. METHODS: The QLQ-OES18, QLQ-STO22 and seven modified items were administered to 300 patients with oesophageal (n=148), junctional (n=66), or gastric cancer (n=86). Semi-structured interviews assessed item and scale preference and multi-trait scaling analyses confirmed the scale structure of the new module (QLQ-OG25). This was further tested for validity. RESULTS: The QLQ-OG25 has six scales, dysphagia, eating restrictions, reflux, odynophagia, pain and anxiety. Scales have good reliability (alpha range 0.67-0.87) and they distinguish between tumour sites and disease stage. Scales do not correlate highly with scores from the core questionnaire, thus indicating that the module was addressing separate HRQL aspects. CONCLUSION: The QLQ-OG25 is recommended to supplement the EORTC QLQ-C30 when assessing HRQL in patients with oesophageal, junctional or gastric cancer.
AIM: To combine and test the EORTC questionnaires for assessing quality of life (HRQL) for oesophageal (QLQ-OES18) and stomach cancer (QLQ-STO22), into a single questionnaire for tumours of the oesophagus, oesophago-gastric junction or stomach. METHODS: The QLQ-OES18, QLQ-STO22 and seven modified items were administered to 300 patients with oesophageal (n=148), junctional (n=66), or gastric cancer (n=86). Semi-structured interviews assessed item and scale preference and multi-trait scaling analyses confirmed the scale structure of the new module (QLQ-OG25). This was further tested for validity. RESULTS: The QLQ-OG25 has six scales, dysphagia, eating restrictions, reflux, odynophagia, pain and anxiety. Scales have good reliability (alpha range 0.67-0.87) and they distinguish between tumour sites and disease stage. Scales do not correlate highly with scores from the core questionnaire, thus indicating that the module was addressing separate HRQL aspects. CONCLUSION: The QLQ-OG25 is recommended to supplement the EORTC QLQ-C30 when assessing HRQL in patients with oesophageal, junctional or gastric cancer.
Authors: Robert C G Martin; Robert M Cannon; Russell E Brown; Susan F Ellis; Sharon Williams; C R Scoggins; Abbas E Abbas Journal: Oncologist Date: 2014-02-24
Authors: Sheraz R Markar; Melody Ni; Suzanne S Gisbertz; Leonie van der Werf; Jennifer Straatman; Donald van der Peet; Miguel A Cuesta; George B Hanna; Mark I van Berge Henegouwen Journal: J Clin Oncol Date: 2020-05-18 Impact factor: 44.544
Authors: K Raynaud; D Seguy; M Rogosnitzky; F Saulnier; F R Pruvot; Philippe Zerbib Journal: Langenbecks Arch Surg Date: 2015-12-21 Impact factor: 3.445
Authors: E Jezerskyte; L M Saadeh; E R C Hagens; M A G Sprangers; L Noteboom; H W M van Laarhoven; W J Eshuis; M I van Berge Henegouwen; S S Gisbertz Journal: World J Surg Date: 2020-03 Impact factor: 3.352
Authors: D A Patel; R Sharda; K L Hovis; E E Nichols; N Sathe; D F Penson; I D Feurer; M L McPheeters; M F Vaezi; David O Francis Journal: Dis Esophagus Date: 2017-05-01 Impact factor: 3.429
Authors: Sara LeGrand; Susan Reif; Kristen Sullivan; Kate Murray; Morgan L Barlow; Kathryn Whetten Journal: Curr HIV/AIDS Rep Date: 2015-12 Impact factor: 5.071